Tablets 200mg

On advice of Microbiology only.

Treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults.

Fidaxomicin (Dificlir®) to be considered as an option for use following a first or second relapse. i.e. as second or third line therapy.
Fidaxomicin to also be considered for patients with severe CDI who are considered to be at high risk for recurrence as per the Public Health England Guidance. e.g. elderly patients with multiple comorbidities who are receiving concomitant antibiotics and those not responding to oral vancomycin.